Application of platelet-rich plasma in rectovaginal fistulas in the patients with ulcerative colitis.
Inflammatory bowel diseases
Platelet-rich plasma
Rectovaginal fistulas
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
25
03
2021
accepted:
06
06
2021
pubmed:
23
6
2021
medline:
19
2
2022
entrez:
22
6
2021
Statut:
ppublish
Résumé
There is a need for other than surgical methods of therapy for small and low rectovaginal fistulas (RVF) in the course of inflammatory bowel diseases (IBD), such as application of fibrin sealants, stem cells, biological therapy, or platelet-rich plasma. The aim of this study was to evaluate the results of the treatment after local application of PRP in aforementioned fistulas, exclusively in the patients with ulcerative colitis (UC). Medical records of 13 patients with small and low-lying, active RVF in the course of UC, and after restorative proctocolectomy for UC were evaluated. Curettage of fistulous tracts was performed with the following application of PRP in all patients. Complete closure of RVF was achieved after the first injection in 4 patients, 3 women healed their fistulas following the second application, and two of them closed RVF after 3 injections. To sum up, the complete closure of RVF was achieved in 9 (69%) patients. Fistulas remained closed from 6 to 12 months. The application of PRP in small, low, and recurrent IBD anal fistulas is effective, simple, and safe with an acceptable rate of healing. This therapy might also precede any further, surgical methods of treatment.
Sections du résumé
BACKGROUND
BACKGROUND
There is a need for other than surgical methods of therapy for small and low rectovaginal fistulas (RVF) in the course of inflammatory bowel diseases (IBD), such as application of fibrin sealants, stem cells, biological therapy, or platelet-rich plasma. The aim of this study was to evaluate the results of the treatment after local application of PRP in aforementioned fistulas, exclusively in the patients with ulcerative colitis (UC).
PATIENTS AND METHODS
METHODS
Medical records of 13 patients with small and low-lying, active RVF in the course of UC, and after restorative proctocolectomy for UC were evaluated. Curettage of fistulous tracts was performed with the following application of PRP in all patients.
RESULTS
RESULTS
Complete closure of RVF was achieved after the first injection in 4 patients, 3 women healed their fistulas following the second application, and two of them closed RVF after 3 injections. To sum up, the complete closure of RVF was achieved in 9 (69%) patients. Fistulas remained closed from 6 to 12 months.
CONCLUSIONS
CONCLUSIONS
The application of PRP in small, low, and recurrent IBD anal fistulas is effective, simple, and safe with an acceptable rate of healing. This therapy might also precede any further, surgical methods of treatment.
Identifiants
pubmed: 34155543
doi: 10.1007/s00423-021-02232-7
pii: 10.1007/s00423-021-02232-7
pmc: PMC8847300
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
429-433Informations de copyright
© 2021. The Author(s).
Références
Zabana Y, Van Domselaar M, Garcia-Planella E et al (2011) Perianal disease in patients with ulcerative colitis: a case-control study. J Crohns Colitis 5:338–341
doi: 10.1016/j.crohns.2011.02.011
Tozer PJ, Lung P, Lobo AJ et al (2018) Review article: pathogenesis of Crohn’s perianal fistula-understanding factors impacting on success and failure of treatment strategies. Aliment Pharmacol Ther 48:260–269
doi: 10.1111/apt.14814
Zinicola R, Nicholls RJ (2004) Restorative proctocolectomy in patients with ulcerative colitis having a recto-vaginal fistula. Colorectal Dis 6:261–264
doi: 10.1111/j.1463-1318.2004.00606.x
Champagne BJ, McGee MF (2010) Rectovaginal fistula. Surg Clin North Am 90(1):69–82
doi: 10.1016/j.suc.2009.09.003
Sonoda T, Hull T, Piedmonte MR, Fazio VW (2002) Outcomes of primary repair of anorectal and rectovaginal fistulas using the endorectal advancement flap. Dis Colon Rectum 45:1622–1628
doi: 10.1007/s10350-004-7249-y
Narang SK, Keogh K, Alam NN et al (2017) A systematic review of new treatments for cryptoglandular fistula in ano. Surgeon 15:30–39
doi: 10.1016/j.surge.2016.02.002
Viscido A, Habib FI, Kohn A et al (2003) Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Pharmacol Ther 17:1263–1271
doi: 10.1046/j.1365-2036.2003.01535.x
Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis 11:135–149
doi: 10.1093/ecco-jcc/jjw169
Kniery KR, Johnson EK, Steele SR (2015) Operative considerations for rectovaginal fistulas. World J Gastrointest Surg 7(8):133–137
doi: 10.4240/wjgs.v7.i8.133
Le ADK, Enweze L, DeBaun MR, Dragoo JL (2020) Current clinical recommendations for use of platelet-rich plasma. Curr Rev Musculoskelet Med 11(4):624–634
doi: 10.1007/s12178-018-9527-7
de la Portilla F, Jiménez-Salido A, Araujo-Miguez A et al (2020) Autologous platelet-rich plasma in the treatment of perianal fistula in Crohn’s disease. J Gastrointest Surg 24(12):2814–3282
doi: 10.1007/s11605-019-04480-x
Moreno-Serrano A, García-Díaz JJ, Ferrer-Márquez M (2016) Using autologous platelet-rich plasma for the treatment of complex fistulas. Rev Esp Enferm Dig 108(3):123–128
pubmed: 26856400
Kontovounisios C, Tekkis P, Tan E et al (2016) Adoption and success rates of perineal procedures for fistula-in-ano: a systematic review. Colorectal Dis 18:441–458
doi: 10.1111/codi.13330
Lindsey I, Smilgin-Humphreys MM, Cunningham C et al (2002) A randomized, controlled trial of fibrin glue vs. conventional treatment for anal fistula. Dis Colon Rectum 45:1608–1615
doi: 10.1007/s10350-004-7247-0
Sentovich SM (2003) Fibrin glue for anal fistulas: long-term results. Dis Colon Rectum 46:498–502
doi: 10.1007/s10350-004-6589-y
Castro-Poceiro J, Fernández-Clotet A, Panés J (2018) Mesenchymal stromal cells in the treatment of perianal fistulas in Crohn’s disease. Immunotherapy 10:1203–1217
doi: 10.2217/imt-2018-0099